US 12,383,608 B2
WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
Hitoshi Ban, Nishinomiya (JP); Masashi Goto, Ibaraki (JP); and Yosuke Takanashi, Osaka (JP)
Assigned to SUMITOMO PHARMA CO., LTD., Osaka (JP); and INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., Suita (JP)
Appl. No. 16/464,950
Filed by Sumitomo Pharma Co., Ltd., Osaka (JP); and INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., Suita (JP)
PCT Filed Nov. 29, 2017, PCT No. PCT/JP2017/042760
§ 371(c)(1), (2) Date May 29, 2019,
PCT Pub. No. WO2018/101309, PCT Pub. Date Jun. 7, 2018.
Claims priority of application No. 2016-233042 (JP), filed on Nov. 30, 2016.
Prior Publication US 2020/0016255 A1, Jan. 16, 2020
Int. Cl. A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 39/001153 (2018.08) [A61K 39/00 (2013.01); A61P 35/00 (2018.01)] 27 Claims
 
1. A composition or kit comprising at least one compound selected from the compound of formula (3):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, or a compound of formula (4):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein C—C are linked together by disulfide bond,
and
cancer antigen peptide D or a pharmaceutically acceptable salt thereof, wherein the cancer antigen peptide D is a peptide which induces WT1-specific helper T cells by binding to an MHC class II molecule and consisting of the amino acid sequence selected from:
 
 (SEQ ID NO: 2)
 
 AYPGCNKRYFKLSHL,
 
 
 
 (SEQ ID NO: 3)
 
 YPGCNKRYFKLSHLQ,
 
 
 
 (SEQ ID NO: 8)
 
 NKRYFKLSHLQMHSRK,
 
 
 
 (SEQ ID NO: 9)
 
 KRYFKLSHLQMHSRK,
 
 
 
 (SEQ ID NO: 11)
 
 RYFKLSHLQMHSRKH,
 
 
 
 (SEQ ID NO: 12)
 
 YFKLSHLQMHSRKHT,
 
 
 
 (SEQ ID NO: 13)
 
 FKLSHLQMHSRKHTG,
 
 
 
 (SEQ ID NO: 14)
 
 KLSHLQMHSRKHTGE,
 
 
 
 (SEQ ID NO: 39)
 
 RYFKLSHLQMHSRK,
 
 
 
 (SEQ ID NO: 40)
 
 YFKLSHLQMHSRK,
 
 
 
 (SEQ ID NO: 41)
 
 FKLSHLQMHSRK,
 
 
 
 (SEQ ID NO: 42)
 
 KLSHLQMHSRK,
 
 
 
 (SEQ ID NO: 43)
 
 AYPGCNKRYFKLSHLQMH,
 
 
 
 (SEQ ID NO: 44)
 
 AYPGCNKRYFKLSHLQMHSRK,
 
 
 
 (SEQ ID NO: 45)
 
 RYFKLSHLQMH,
 
 
 
 (SEQ ID NO: 46)
 
 GCNKRYFKLSHL,
 
 
 
 (SEQ ID NO: 47)
 
 FKLSHLQMHSRKHTGE,
 
 
 
 (SEQ ID NO: 48)
 
 RYFKLSHLQMHSRKHT,
 
 
 
 (SEQ ID NO: 49)
 
 RYFKLSHLQMHSRKHTGE,
 
 
 
 (SEQ ID NO: 50)
 
 KLSHLQMHSRKH,
 
 
 
 (SEQ ID NO: 52)
 
 AYPGCNKRYFKLSHLQMHSR,
 
 
 
 (SEQ ID NO: 53)
 
 AYPGCNKRYFKLSHLQMHS,
 
 
 
 (SEQ ID NO: 54)
 
 AYPGCNKRYFKLSHLQM,
 
 
 
 (SEQ ID NO: 55)
 
 AYPGCNKRYFKLSHLQ,
 
 
 
 (SEQ ID NO: 56)
 
 YFKLSHLQMHSRKHTGE,
 
 
 
 (SEQ ID NO: 57)
 
 RYFKLSHLQMHSRKHTG,
 
 
 
 (SEQ ID NO: 58)
 
 RYFKLSHLQMHSR,
 
 
 
 (SEQ ID NO: 59)
 
 RYFKLSHLQMHS,
 
 
 
 (SEQ ID NO: 60)
 
 RYFKLSHLQM,
 
 
 
 (SEQ ID NO: 61)
 
 YPGCNKRYFKLSHL,
 
 
 
 (SEQ ID NO: 62)
 
 PGCNKRYFKLSHL,
 
 
 
 (SEQ ID NO: 63)
 
 CNKRYFKLSHL,
 
 
 
 (SEQ ID NO: 64)
 
 NKRYFKLSHL,
 
 
 
 (SEQ ID NO: 65)
 
 KLSHLQMHSRKHTG,
 
 
 
 (SEQ ID NO: 66)
 
 KLSHLQMHSRKHT,
 
 and
 
 
 
 (SEQ ID NO: 67)
 
 KLSHLQMHSRK,
or a peptide consisting of the amino acid sequence that differs from the amino acid sequence of the cancer antigen peptide D by alteration of one amino acid residue, provided that the cancer antigen peptide D is not SEQ ID NO:6, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 38, or SEQ ID NO:51.